Log In
Print this Print this

Praluent, alirocumab (REGN727, SAR236553)

Also known as: SAR236553/REGN727

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionHuman mAb targeting proprotein convertase subtilisin/kexin type 9 (PCSK9)
Molecular Target Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentMarketed
Standard IndicationHypercholesterolemia
Indication DetailsTreat autosomal dominant hypercholesterolemia (ADH); Treat heterozygous familial hypercholesterolemia (HeFH); Treat hypercholesterolemia; Treat hypercholesterolemia and familial hypercholesterolemia (FH) in patients at high cardiovascular risk with insufficient response to statin treatment; Treat hypercholesterolemia and heterozygous familial hypercholesterolemia (HeFH); Treat primary hypercholesterolemia
Regulatory Designation U.S. - Priority Review (Treat hypercholesterolemia);
U.S. - Special Protocol Assessment (Treat hypercholesterolemia);
EU - Standard Review (Treat hypercholesterolemia)
PartnerRegeneron Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today